A Bundle of the "Top 10" Outpatient Parenteral Antimicrobial Therapy Publications in 2023.
| Autor: | Childs-Kean LM; College of Pharmacy, University of Florida, Gainesville, Florida, USA., Beieler AM; Infectious Diseases Clinic, Harborview Medical Center, Seattle, Washington, USA., Cortés-Penfield N; Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA., Keller SC; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Rivera CG; Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA., Ryan KL; Department of Pharmacy, University of New Mexico Hospital, Albuquerque, New Mexico, USA., Yoke LH; Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.; Allergy and Infectious Disease Division, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA., Mahoney MV; Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Open forum infectious diseases [Open Forum Infect Dis] 2024 Oct 29; Vol. 11 (11), pp. ofae635. Date of Electronic Publication: 2024 Oct 29 (Print Publication: 2024). |
| DOI: | 10.1093/ofid/ofae635 |
| Abstrakt: | Outpatient parenteral antimicrobial therapy (OPAT) has become more common in infectious diseases practice settings. Similarly, OPAT-related publications have also increased. The objective of this article was to summarize clinically important OPAT-related publications from 2023. Eighty-one articles were found on initial search, with 52 meeting inclusion criteria. A survey containing the 19 articles that had at least 1 citation was sent to an email listserv of multidisciplinary clinicians with OPAT experience. This article summarizes the "top 10" 2023 OPAT articles from the survey results. Competing Interests: Potential conflicts of interest. L. M. C.-K. has received honoraria from the American Society of Health-System Pharmacists and the American Association of Colleges of Pharmacy. A. M. B. is co-chair of the Infectious Diseases Society of America (IDSA) Advanced Practice Provider interest group. S. C. K. has received honoraria from McGraw Hill Educational; grant support from the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, and the Department of Veterans Affairs. M. V. M. has received research funding from Merck and has been a consultant to BD Biosciences, Cidara Therapeutics, GSK, and Pfizer. C. G. R. has received research funding and consulting fees from Gilead Sciences; honoraria from Jobson Health, Continuing Education Network, Ce Impact, Insmed, and Gilead Sciences; and travel/lodging support from Ce Impact. K. L. R. has received honoraria from PharmCon. L. H. Y. has received honoraria from Washington Academy of Physician Assistants, Journal of the Advanced Practitioner in Oncology, and American Society for Transplantation and Cellular Therapy; has received payment for expert testimony from McNabola Law Group; is a board member of the Washington Academy of Physician Assistants; and is co-chair of the IDSA Advanced Practice Provider interest group. N. C.-P. reports no potential conflicts. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|